FindTrial
Sign In

To study the usefulness of Fosfomycin in the treatment of drug resistant urinary tract infections (UTI) among diabetic patients.

Prevalence of Antibiotic resistance and Effectiveness of Fosfomycin in Carbapenem- resistant and Carbapenem-susceptible Multidrug-Resistant Enterobacterales (MDRE) Bacteriuria in Diabetic patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051236
Enrollment
40
Registered
2023-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N390- Urinary tract infection, site notspecified

Interventions

Intervention1: Prescribing Fosfomycin drug: FOSFOMYCIN (3g) is to be taken orally after mixing the whole sachet with water on Day 0 of confirmed diagnosis and then follow up with the patient after 5 d

Sponsors

Dr Sreemedha Choudhury
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: UTI Patients who are known cases of Diabetes Mellitus, having UTI symptoms like frequency, urgency, burning micturition etc.

Exclusion criteria

Exclusion criteria: Patient refusing to participate in the study Psychotic Patients Patients with asymptomatic bacteriuria Pregnant females

Design outcomes

Primary

MeasureTime frame
Effectiveness of Fosfomycin drug in Carbapenem-susceptible and Carbapenem-resistant Multidrug Resistant Enterobacterales (MDRE) UTI in diabetic patientsTimepoint: Baseline(1st visit) and 2 weeks—

Secondary

MeasureTime frame
Study the susceptibility profile of MDRE in diabetic UTI patientsTimepoint: Baseline and at 2 weeks;To identify the risk factors associated with MDRETimepoint: Baseline;Try to assess the prevalence of MDRE UTI in diabetic patients in a tertiary healthcare centre of AligarhTimepoint: Baseline—

Countries

India

Contacts

Public ContactSREEMEDHA CHOUDHURY

JAWAHARLAL NEHRU MEDICAL COLLEGE, A.M.U.

dr.farhan.k@gmail.com9759468300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026